An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...